Achillion Pharmaceuticals announced sustained viral response, or SVR4, results of 85%-100% from an ongoing multi-dose Phase 2 trial evaluating 12 weeks of dosing with sovaprevir, a once-daily protease inhibitor, in combination with pegylated interferon plus ribavirin (P/R) followed by an additional 12 weeks of P/R. In addition, the Company announced today that ACH-3102, a second-generation pan-genotypic NS5A inhibitor, has been safe and well tolerated by healthy volunteers in both single and 14-day multiple ascending dose groups. Further, enrollment of patients in a Phase 1 proof-of-concept clinical trial to evaluate the safety and efficacy of ACH-3102 in patients with genotype 1 HCV has been initiated.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?